Allakos Presents Data from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting
The following posters are being presented:
Siglec-8, a Novel Selective Target for Eosinophilic Gastrointestinal Diseases (EGIDs) Found on Eosinophils and Mast Cells in Human Tissue (P2591)
B. Youngblood, E. Brock, C. Bebbington, N. Tomasevic, H. Rasmussen, K. Peterson
This study examined the number and phenotype of white blood cells isolated from patient biopsies with eosinophilic gastritis (EG) and eosinophilic esophagitis (EoE). The poster concludes that:
- Siglec-8 is selectively expressed on eosinophils and mast cells at high levels in biopsies from patients diagnosed with EG and EoE
- Eosinophils and mast cells are significantly increased in biopsies from patients diagnosed with EG and EoE
- Mast cells were elevated to the same extent as eosinophils in biopsies from patients diagnosed with EG and EoE
- Eosinophils and mast cells in EG biopsies display an activated phenotype, suggesting eosinophils and mast cells are pathogenic in EG as well as other EGIDs
- AK002 treatment of eosinophils and mast cells from EG biopsies was shown to normalize the expression of inflammatory cytokines and cell surface markers of activation
The data suggest that targeting Siglec-8 with AK002 may represent a novel approach to treat EGIDs.
Novel Anti-Siglec-8 Antibody Reduces Eosinophil and Mast Cell Infiltration in a Mouse Model of Eosinophilic Gastritis and Gastroenteritis (P2540)
B. Youngblood, E. Brock, J. Leung, C. Bebbington, N. Tomasevic
This study examined the activity of the Company’s anti-Siglec-8 monoclonal antibody (mAb) AK002 in a mouse model of eosinophilic gastritis (EG) and gastroenteritis (EGE). The study showed that AK002 significantly reduced the number of eosinophils and mast cells in the stomach, small intestine, and blood compared to isotype control mAb-treated mice. In addition, mice treated with AK002 had reduced levels of inflammatory mediators in intestinal tissue and blood compared to isotype control treated mice.
About Allakos’ Eosinophilic Gastritis Program
About Eosinophilic Gastritis and Eosinophilic Gastroenteritis
Eosinophilic gastritis (EG) and eosinophilic gastroenteritis (EGE) are severe inflammatory diseases characterized by the presence of high levels of eosinophils in the stomach and/or the stomach and duodenum. Common symptoms of the disease include abdominal pain, nausea, vomiting, diarrhea, malnutrition and weight loss. The estimated prevalence of EG/EGE in
Allakos is a clinical stage company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. AK002 has completed two Phase 1 trials, one in healthy volunteers and a single ascending dose trial in patients with indolent systemic mastocytosis. AK002 demonstrated pharmacodynamic activity in both trials and in the trial involving patients with indolent systemic mastocytosis, patients reported improvements in their symptoms. AK002 is being tested in a Phase 2 trial for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis. In addition, Allakos is conducting multiple-dose trials with AK002 in chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. For more information, please visit the Company's website at www.allakos.com.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding the potential benefits of AK002 and the ability to develop AK002 and other antibodies to treat eosinophil and mast cell related diseases, the timing of top-line results from the Phase 2 clinical trial in patients with eosinophilic gastritis and eosinophilic gastroenteritis, and estimates of the number of patients with eosinophilic gastritis and eosinophilic gastroenteritis in
Adam Tomasi, COO, CFO email@example.com Media Contact: Denise Powelldenise@redhousecomms.com
Source: Allakos Inc.